Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s 27% gain. Investor sentiment toward PFE has been negatively impacted by ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine demand and pipeline ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Stock valuations still matter ... it should generate significantly greater sales by the end of the decade. Pfizer(NYSE: PFE) was the only drugmaker to beat Moderna to market in the U.S. with ...